Diuretic Drugs Market to Record a CAGR of 5.44%, Increasing Incidence of Hypertension Among People to Drive Growth – Technavio – QNT Press Release

[ad_1]

NEW YORK, Sept. 29, 2022 /PRNewswire/ — The report “Diuretic Drugs Market by Product Type and Geography – Forecast and Analysis 2022-2026″ has been added to Technavio’s offerings. The market size is anticipated to grow by USD 95.64 million from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 5.44% during the forecast period.

Technavio provides a comprehensive report summary describing the market size and forecast along with research methodology. The FREE sample report is available in PDF format

The increasing incidence of hypertension due to the increasing pressure on the walls of the arteries is driving the growth of the market. Hypertension raises the risk of diseases such as kidney failure, stroke, and heart disease. It can also affect the brain by causing a stroke, TIA, dementia , or mild cognitive impairment. The prevalence of hypertension in low- and middle-income countries is high. Hypertension has no warning signs or symptoms. Hence, it is also known as the silent killer. It can also cause bone loss, sexual dysfunction, and conditions such as obstructive sleep apnea (OSA). Thus, the rise in the number of patients with hypertension owing to obesity, diabetes, CKD, stress, sedentary lifestyle, and alcohol addiction will drive the growth of the market during the forecast period.

The diuretic drugs market is concentrated, and the vendors are deploying growth strategies such as investments in R&D to compete in the market. The vendors among vendors is high owing to the fast-growing sales of some of the diuretic drugs. In addition, a strong pipeline of drugs to treat high blood pressure and edema will intensify the competition further during the forecast period. The market will record the approvals for several promising drugs, which will intensify competition among vendors.

The diuretic drugs market report includes information on the product launches, sustainability, and prospects of leading vendors including AbbVie Inc., Akorn Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Casper Pharma, Hikma Pharmaceuticals Plc, Lannett Co. Inc., Novartis AG, Monarch Pharmachem, Pfizer Inc., Padagis US LLC, Sanofi, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., VITARIS AG, Validus Pharmaceuticals LLC, and Zydus Lifesciences Ltd.

Technavio’s reports provide key strategic initiatives used by vendors, along with key news and the latest developments. View our FREE PDF Sample Report Now

The report includes competitive analysis, a proprietary tool to evaluate and analyze the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into categories such as growth strategies, financial performance over the last three years, new product launches, innovation score, growth in market share, investments, etc.

• By product type, the market has been classified into loop diuretics, thiazide diuretics, and others. The loop diuretic drugs will contribute the largest share of the market during the forecast period.
• By geography, the market has been classified into North America, Europe, Asiaand Rest of World (ROW). North America will have the largest share of the market during the forecast period.

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report

Motion Sickness Drugs Market by Product and Geography – Forecast and Geography 2022-2026: The motion sickness drugs market is projected to grow by USD 119.64 million from 2021 to 2026.

Antihypertensive Drugs Market by Type and Geography – Forecast and Analysis 2022-2026: The antihypertensive drugs market share is expected to increase by USD 5.87 billion from 2021 to 2026.

Full story available on Benzinga.com

[ad_2]

Source link